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Abstract
Increased plasticity, migratory and immunosuppressive abilities characterize mesenchymal stromal cells (MSC) which enable
them to be active participants in the development of hypoxic solid tumours. Our understanding of the oncogenic
adaptation of MSC to hypoxia however lacks the identification and characterization of specific biomarkers. In this study, we
assessed the hypoxic regulation of 3BP2/SH3BP2 (Abl SH3-binding protein 2), an immune response adaptor/scaffold protein
which regulates leukocyte differentiation and motility. Gene silencing of 3BP2 abrogated MSC migration in response to
hypoxic cues and generation of MSC stably expressing the transcription factor hypoxia inducible factor 1alpha (HIF-1a)
resulted in increased endogenous 3BP2 expression as well as cell migration. Analysis of the 3BP2 promoter sequence
revealed only one potential HIF-1a binding site within the human but none in the murine sequence. An alternate early
signalling cascade that regulated 3BP2 expression was found to involve membrane type-1 matrix metalloproteinase (MT1-
MMP) transcriptional regulation which gene silencing abrogated 3BP2 expression in response to hypoxia. Collectively, we
provide evidence for a concerted HIF-1a/MT1-MMP signalling axis that explains the induction of adaptor protein 3BP2 and
which may link protein binding partners together and stimulate oncogenic MSC migration. These mechanistic observations
support the potential for malignant transformation of MSC within hypoxic tumour stroma and may contribute to evasion of
the immune system by a tumour.
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Introduction
Mesenchymal stromal cells (MSC), most commonly isolated
from the bone marrow, are a population of pluripotent adult stem
cells that can differentiate into many mesenchymal phenotypes
[1,2]. In fact, recruitment of MSC by experimental vascularizing
tumours resulted in the incorporation of MSC within the tumor
architecture [3,4] which, combined to intrinsic immunomodula-
tory mechanisms, implies that they must also respond to tumour-
derived growth factor cues [5,6]. Importantly, the microenviron-
ment and stroma required for the evolution and progression of
solid tumours has been investigated over the past few years, and
MSC, which are the progenitors of stromal cells and fibroblasts,
have been found to interact with cancer cells [7]. Consequently,
their potential contribution to tumour development implies that
MSC must adapt to the low oxygen environment and nutrient
deprivation that characterizes hypoxic tumours.
Homing of MSC to tumours is thought to be among the earliest
phenomenon of MSC-cancer interactions, as was recently reported
in a mouse model where injected human MSC could be found
preferentially migrating to implanted human melanoma tumours
[3].Subsequently,studieshaveshownMSChoming totumoursand
even to sites of metastasis [8]. Furthermore, cotransplantation of
MSC with melanoma cells in mice enhanced tumour engraftment
and growth [9]. These data are in agreement with observations that
vascular progenitors derived from bone marrow stromal cells are
recruited by tumours both in vivo and in vitro [5]. The sum of this
evidence, in line with their increased ability to migrate under an
atmosphere of low oxygen [10], suggests that MSC are active
participants in the development of hypoxic solid tumours.
In order to survive within the stressful hypoxic tumour
microenvironment, cells have developed a coordinated set of
responses orchestrating their adaptation to hypoxia. The outcomes
of such cellular responses to hypoxia are aggressive disease,
resistance to therapy, and decreased patient survival [11]. A critical
mediator of the hypoxic response is the transcription factor hypoxia
inducible factor 1 (HIF-1) which upregulates expression of proteins
that promote angiogenesis, anaerobic metabolism, and many other
survival pathways [12]. Regulation of HIF-1a, a component of the
HIF-1 heterodimer, occurs at multiple levels including translation,
degradation, and transcriptional activation, and serves as a
testimony to the central role of HIF-1. Unfortunately, the roles
played by many of the individual molecular components which
merge these different signals remain undefined. Adaptor proteins
which link protein binding partners together and stimulate
formation of signalling complexes [13] play an important role in
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regulate cell mobilization, oncogenesis, metabolic and immunologic
adaptative capacities. Among these, the adaptor protein 3BP2
was originally identified as a protein that interacts with the Src
homology (SH) 3 domain of the protein tyrosine kinase Abl [14].
3BP2 is predominantly expressed in hematopoietic/lymphoid
tissues and its SH2 domain has been shown to associate in vitro
with Syk, ZAP70, linker for activation of T cells, Grb2, phospho-
lipase Cc1, and cbl from activated T cell lysates [15]. Whether any
3BP2 functions are linked to MSC’s oncogenic transformation
activities, including extracellular matrix (ECM) degradation and
directed cell migration, is currently unknown.
While most of the matrix metalloproteinases (MMP) are secreted,
MT1-MMP is a membrane-associated MMP regulated by hypoxia
[10] and, aside from its well-known role in the activation of
proMMP-2 and intrinsic proteolytic activity towards ECM
molecules, drives MSC mobilization [16,17]. More importantly,
its cytoplasmic domain was recently shown to link adaptor protein
p130Cas [18] and Src-mediated events through the phosphoryla-
tion of its intracellular domain [19]. In light of such scaffolds taking
place in MT1-MMP cellular signalling, MT1-MMP functions
associated with platelet-mediated calcium mobilization [20],
regulation of cell death/survival bioswitch [21,22], and regulation
of proinflammatory signalling [23,24] have been reported. Given
that hypoxia is a condition that promotes oncogenic processes, we
questioned whether any HIF-1a/3BP2/MT1-MMP signalling axis
may contribute to the hypoxic adaptation of MSC.
Materials and Methods
Materials
Sodium dodecylsulfate (SDS) and bovine serum albumin (BSA)
were purchased from Sigma (Oakville, ON). Cell culture media
were obtained from Life Technologies (Burlington, ON). Electro-
phoresis reagents were purchased from Bio-Rad (Mississauga, ON).
The enhanced chemiluminescence (ECL) reagents, protein G- and
A-coupled sepharose were from Amersham Pharmacia Biotech
(Baie d’Urfe ´, QC). Micro bicinchoninic acid protein assay reagents
were from Pierce (Rockford, IL). The polyclonal antibodies were
purchased and generated against the MT1-MMP catalytic domain
(Chemicon), the MT1-MMP cytoplasmic domain (Abcam), 3BP2
(Abcam) and GAPDH (Advanced Immunochemicals).
Cell cultures and experimental hypoxic conditions
This study was approved by the ‘‘Comite ´ Institutionnel des
Risques Biologiques’’ through the delivery of a written certificate
(#10-CIRB-53.3.5). Bone marrow-derived mesenchymal stromal
cells (MSC) were isolated from the whole femur and tibia bone
marrow of C57BL/6 female mice; cells were cultured and
characterized by flow cytometry as previously described [25].
cDNA construct generation and transduction of the MSC-HIF-1a
was performed and extensively described previously [26]. Hypoxic
culture conditions were attained by incubation of confluent cells in
an anaerobic box for up to 48 hours [26]. The oxygen was
maintained at 1% by a compact gas oxygen controller Proox
model 110 (Reming Bioinstruments Co., Redfield, NY) with a
residual gas mixture composed of 94% N2 and 5% CO2. Re-
oxygenation was kept at its minimum through rapid processing
(less than 10 seconds) of the hypoxic cells for total RNA and
protein extractions. Serum starvation is classically performed by
culturing the cells in high glucose Dulbecco’s modified Eagle’s
medium (DMEM; GibcoBRL) and 100 units/ml Penicillin/
Streptomycin, and from which the 10% inactivated fetal bovine
serum (iFBS) (Hyclone Laboratories, Logan, UT) was removed.
Immunoblotting procedures
Cells from MSC or MSC-HIF-1a were lysed and proteins were
separated by SDS–polyacrylamide gel electrophoresis (PAGE).
After electrophoresis, proteins were electrotransferred to poly-
vinylidene difluoride membranes and immunoreactive material
was visualized by enhanced chemiluminescence as described
previously [26].
Cell survival and migration assays
MSC lysed in Apo-Alert lysis buffer (Clontech, Palo Alto, CA)
were assessed for apoptotic cell death by the fluorometric caspase-
3 activity as previously described by us [25]. Upon treatment,
floating cells were aspirated and removed. Adherent MSC or
MSC-HIF-1a were then trypsinized and viability evaluated by
Trypan blue exclusion staining. Majority of the cells were found
viable and seeding of 10
5 viable cells was performed on 0.15%
gelatin/PBS precoated Transwells (Corning/Costar; Acton, MA;
8-mm pore size) assembled in 24-well Boyden chambers which
were filled with 600 ml of serum-free media. Cell migration was
allowed to proceed for 6–24 hours at 37uCi n5 %C O 2. The
migration was quantified by analyzing at least ten random fields
per filter for each independent experiment as described previously
[26].
Total RNA isolation, cDNA synthesis and real-time
quantitative RT-PCR
Total RNA was extracted from MSC monolayers using TRIzol
reagent (Life Technologies, Gaithersburg, MD). For cDNA
synthesis, 1 mg of total RNA was reverse-transcribed into cDNA
using a high capacity cDNA reverse transcription kit (Applied
Biosystems, Foster City, CA). cDNA was stored at 280uC prior to
PCR. Gene expression was quantified by real-time quantitative
PCR using iQ SYBR Green Supermix (BIO-RAD, Hercules, CA).
DNA amplification was carried out using an Icycler iQ5 (BIO-
RAD, Hercules, CA) and product detection was performed by
measuring binding of the fluorescent dye SYBR Green I to double-
stranded DNA. The following primer sets were provided by
QIAGEN (Valencia, CA): HIF-1a (Mm_Hif1a_1_SG QT0103
9542), 3BP2 (Mm_Sh3bp2_1_SG QT00100464), MT1-MMP
(Mm_Mmp14_1_SG QT01064308), VEGF (Mm_Vegfa_1_SG
QT00100464), b-Actin (Mm_Actb_2_SG QT01136772). The rela-
tive quantities of target gene mRNA against an internal control, b-
Actin RNA, were measured by following a DCT method employing
an amplification plot (fluorescence signal vs. cycle number). The
difference (DCT) between the mean values in the triplicate samples
of target gene and those of b-Actin RNA were calculated by iQ5
Optical System Softwareversion2.0(BIO-RAD,Hercules,CA)and
the relative quantified value (RQV) was expressed as 2
2DC
T.
Transfection method and RNA interference
MSC were transiently transfected with 20 nM siRNA against
HIF-1a (Mm_Hif1a_1 HP siRNA, SI00193011), MT1-MMP
(Mm_Mmp14_2 HP siRNA, SI00177800), 3BP2 (Mm_Sh3bp2_4
HP siRNA, SI00204218) or scrambled sequences (AllStar
Negative Control siRNA, 1027281) using Lipofectamine 2000
transfection reagent (Invitrogen, CA). HIF-1a-, 3BP2- and MT1-
MMP-specific gene knockdown was evaluated by qRT-PCR as
described above. Small interfering RNA and mismatch siRNA
were synthesized by QIAGEN and annealed to form duplexes.
Statistical data analysis
Data are representative of three or more independent experi-
ments. Statistical significance was assessed using Student’s
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significant and an asterisk identifies such significance in the figures.
Results
Hypoxic culture conditions upregulate 3BP2 gene
expression
MSC were serum-starved and cultured under hypoxic conditions
as described in the Methods section. Total RNA was then extracted
and qRT-PCR performed. We found that hypoxia significantly
induced HIF-1a transcript levels (Fig. 1, black bars) in agreement
with previous reports [26,27]. Moreover, 3BP2, VEGF and MT1-
MMP gene expression were also induced. These observations suggest
that 3BP2 transcriptional regulation occurs in MSC upon low oxygen
tension culture conditions. Whether HIF-1a was specifically involved
in direct 3BP2 gene regulation was next explored through sequence
promoter analysis. An approximate 1,000 bp sequence upstream of
the ATG coding sequence of the respective human (NCBI source
NC_000004.11 and located on human chromosome 4 at location
2,821,348–2,822,347) and murine (NCBI source NC_000071.5 and
located on mouse chromosome 5 at location 3,488,412–3,489,415)
3BP2 gene promoter sequence was analyzed for HIF putative
transcription factor binding sites with PROMO 3.0 (http://alggen.lsi.
upc.es/) using version 8.3 of the TRANSFAC database. Only
one core consensus sequence of the hypoxia responsive elements
(A_G)CGT(G_C)C (228/223) was found in the human. None was
found in the murine sequence analyzed (data not shown). This
suggests that alternate players may be involved in the molecular
cascade that leads to 3BP2 expression through HIF.
Gene silencing of HIF-1a antagonizes the effects of
hypoxia on 3BP2 gene and protein expression
In order to assess the potential contribution of HIF-1a to 3BP2
gene and protein expression regulation under hypoxic culture
conditions, gene silencing strategies were employed to specifically
and efficiently down-regulate HIF-1a gene expression in MSC
(Fig. 2A, left panel). Such knockdown did not trigger apoptotic cell
death as assessed through caspase-3 activity (Fig. 2A, right panel).
Mock (scrambled mismatched siRNA) or siHIF-1a-transfected
MSC were generated by transient transfection as described in the
Methods section. Cells were then cultured under hypoxic culture
conditions for 48 hours, total RNA was extracted and qRT-PCR
was used to assess 3BP2 gene expression. While 3BP2 gene
expression was induced by hypoxia in Mock-transfected cells, we
found that its gene expression was efficiently reduced in siHIF-1a-
transfected MSC (Fig. 2B). 3BP2 protein expression was also
assessed in Mock- and in siHIF-1a-transfected cells that were
subsequently cultured under hypoxic conditions (Fig. 2C). While
3BP2 protein expression was increased by hypoxia with a maximal
plateau expression occurring between 24 and 48 hours in Mock
cells, those cells where HIF-1a gene expression was abrogated
(.78%) were unable to increase 3BP2 (Fig. 2D). The relevance of
HIF-1a was also assessed on the transcriptional regulation of
vascular endothelial growth factor (VEGF) and of membrane type-
1 matrix metalloproteinase (MT1-MMP), two important players in
MSC survival and mobilization processes [10,16,17]. Both the
VEGF and MT1-MMP transcript levels were found induced by
hypoxic culture conditions, while such regulation was abrogated in
siHIF-1a-transfected MSC (data not shown). Consequently,
expression of HIF-1a is required for 3BP2 gene and protein
regulation upon hypoxia.
3BP2 silencing abrogates MSC migration in response to
hypoxic culture conditions
In order to assess any 3BP2-mediated cellular impact, cell
migration was monitored under normoxic or hypoxic culture
conditions. 3BP2 gene silencing was performed (Fig. 3A, upper
and middle panels) and found not to trigger apoptotic cell death
(Fig. 3A, lower panel). While 3BP2 silencing did not affect basal
MSC migration under normoxic conditions (Fig. 3B), cells in
which 3BP2 expression was abrogated were unable to respond to
hypoxic cues (Fig. 3C, black bars). This suggests that 3BP2 is
required for the hypoxic adaptation of MSC that is reflected by an
increase in MSC migration.
Constitutive expression of an oxygen-dependent
degradation domain HIF-1a mutant triggers 3BP2 gene
and protein expression
Recently, experimental evidence has shown that upregulation of
HIF-1a plays a pivotal role in hypoxia-induced MSC mobiliza-
tion, possibly acting via its downstream genes VEGF and SDF-1a
[28]. To date, no demonstration of the direct role of HIF-1a
overexpression itself was performed. In order to recreate the
hypoxic culture conditions that trigger HIF-1a expression in
MSC, we generated a deletion mutant of HIF-1a (HIF-1aD ODD)
which causes constitutive expression of HIF-1a, and stably
transfected MSC with such construct as described in the Methods
section. We found that MSC constitutively and stably expressing
HIF-1aD ODD (MSC-HIF-1a) exhibited an increased intrinsic
ability to migrate (Fig. 4A). Such increased migratory potential has
been documented previously by us [10,26] and, although
speculative, may potentially involve autocrine regulation through
hypoxia-regulated growth factor expression. This may provide
efficient mobilization and adaptive behaviour of MSC to oxygen
deprived environment. When cell lysates and total RNA were
extracted from MSC or MSC-HIF-1a, we found that 3BP2
protein (Fig. 4B) and gene (Fig. 4C) expression were significantly
increased in MSC-HIF-1a cells. Noteworthy, 3BP2 gene silencing
abrogated MSC-HIF-1a migration to levels equivalent to basal
MSC migration (Fig. 4D). This observation confirms that 3BP2
expression is among the mediators involved in the response to
hypoxic cues and downstream of HIF-1a signaling.
Figure 1. Hypoxic culture conditions upregulate 3BP2 gene
expression. Subconfluent MSC were serum-starved and cultured
under normoxic (5% CO2 and 95% air; white box) or hypoxic (1% O2,5 %
CO2 and 94% N2; black box) conditions for 18 hours. Total RNA was
extracted and quantitative reverse transcription-polymerase chain
reaction was performed in order to assess 3BP2, HIF-1a, VEGF and
MT1-MMP gene expression levels. Values are means of two indepen-
dent experiments, each performed in triplicates. Bars, 6SD.
doi:10.1371/journal.pone.0021511.g001
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expression of 3BP2 in MSC
Classical roles for MT1-MMP are those involved in directed
ECM degradation and subsequent cell migration [29]. New
alternate roles highlight MT1-MMP as a signalling molecule since
its intracellular cytoplasmic domain has been shown to trigger
RhoA and Erk transduction pathways [30,31]. Moreover,
increases in MT1-MMP expression correlated with increased
MSC migration in response to hypoxia [10]. Since siHIF-1a
abrogated both 3BP2 (Fig. 2) and MT1-MMP (not shown)
expression in response to hypoxia, we tested whether a signalling
axis might regulate crosstalk between MT1-MMP and 3BP2. We
first used gene silencing strategies to down-regulate MT1-MMP
gene expression and to assess its specific contribution to 3BP2 gene
regulation under hypoxic culture conditions. MSC were transient-
ly transfected with scrambled sequences (Mock) or with MT1-
MMP siRNA as described in the Methods section. Cells were then
cultured under normoxic or hypoxic culture conditions, total RNA
was extracted and qRT-PCR was used to assess MT1-MMP and
HIF-1a gene expression. We found that MT1-MMP gene
expression was significantly reduced in siMT1-MMP transfected
cells while HIF-1a gene expression remained unaffected (Fig. 5A).
3BP2 gene expression was then assessed in Mock-transfected and
in siMT1-MMP-transfected MSC in response to hypoxic culture
conditions. We found that 3BP2 gene expression was induced by
in Mock-transfected cells reaching a plateau at 12 hours of
hypoxia, while such induction was abrogated in siMT1-MMP-
transfected cells (Fig. 5B). 3BP2 protein expression data were also
analyzed and support those of the gene expression regulation of
3BP2 in that siMT1-MMP-transfected MSC did not exhibit
increased 3BP2 expression due to hypoxia (Fig. 5C). Consequent-
ly, expression of MT1-MMP is a prerequisite for 3BP2
transcriptional regulation upon hypoxia.
MT1-MMP overexpression upregulates 3BP2 gene and
protein expression
To test whether MT1-MMP-mediated signalling was involved
in the regulation of 3BP2 expression, we short-circuited hypoxia-
mediated signalling by directly overexpressing either a full-length
wild-type (Wt) recombinant MT1-MMP or its cytoplasmic-
truncated form (D-cyto) in MSC. Total RNA was thereafter
extracted and 3BP2 gene expression assessed by qRT-PCR and
compared to Mock-transfected MSC. 3BP2 gene expression was
increased in Wt-MT1-MMP-transfected MSC but not in cells that
overexpressed the D-cyto-MT1-MMP (Fig. 6A). Expression of
both recombinant proteins, which retained their extracellular
catalytic domain intact, led to functional activation of proMMP-2
at the cell surface as assessed by zymography of the respective
conditioned media (Fig. 6B). Transfection efficiency was further
assessed by measuring expression of the individual MT1-MMP
recombinant forms. Full length and D-cyto-MT1-MMP forms
were detected when membranes were probed with anti-MT1-
MMP generated against the catalytic domain (Fig. 6C), while only
the full length MT1-MMP was detected when using the anti-MT1-
MMP cytoplasmic domain antibody (Fig. 6C). Using the anti-
3BP2 protein expression further confirmed the signalling axis that
Figure 2. Gene silencing of HIF-1a antagonizes the effects of hypoxia on 3BP2 gene and protein expression. MSC were transiently
transfected with scrambled sequences (Mock, white bars, open circles) or HIF-1a siRNA (black bars, closed circles) as described in the Methods
section. Cells were then cultured under normoxic or hypoxic culture conditions as described in the legend of Fig. 1. (A) Apoptotic cell death was
assessed using the fluorometric caspase-3 activity assay as described in the Methods section. Concanavalin-A-treated MSC (grey bars) was used as a
positive inducer of caspase-3 [16]. Total RNA was extracted, and qRT PCR was used to assess 3BP2 and HIF-1a transcript levels. (B) 3BP2 gene
expression was assessed by qRT-PCR in Mock-transfected and in siHIF-1a-transfected cells that were subsequently cultured under hypoxic conditions.
(C) Mesenchymal stromal cells were transiently transfected with scrambled sequences or HIF-1a siRNA as described in the Methods section. Cells
were then cultured under normoxic or hypoxic culture conditions, cell lysates were isolated, western blotting and immunodetection was performed
with anti-3BP2 and anti-GAPDH antibodies. A representative blot is shown out of two. (D) Scanning densitometry was used to assess protein
expression described in panel C, and the ratio of 3BP2/GAPDH expression was represented. Values in (A) and (B) are means of two independent
experiments, each performed in triplicates (*p,0.05 versus mock control in (A) or mock at time=0 hr hypoxia in (B)); Bars, 6SD.
doi:10.1371/journal.pone.0021511.g002
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of 3BP2, as only the Wt form of MT1-MMP led to increased
protein levels of 3BP2 (Fig. 6C).
Discussion
Molecular markers associated with MSC are thought to
characterize the brain tumour-initiating cells involved in the
development of hypoxic solid tumours such as glioblastomas [32],
the most common and aggressive primary brain cancer [33]. It is
also believed that a subset of primary glioblastomas derive from
transformedstem cellspossessing MSC-likeproperties and retaining
partial phenotypic aspects of the MSC nature within the tumours’
hypoxic environment [32]. Accordingly, exogenously delivered
human MSC were found to localize to human gliomas after
intravascular delivery [4]. While VEGF-A was demonstrated to
contribute to glioma-induced migration of human MSC [34], this
raisesthe possibility that endogenous MSC may further be recruited
into hypoxic gliomas during tumorigenesis and may contribute to
the physiological growth of brain tumours in situ. More recently,
MSC implanted directly within the central nervous system (CNS) to
treat experimental autoimmune encephalomyelitis were found to
produce local pathology of yet unknown consequences as reflected
by the formation of cellular masses within brain parenchyma [35].
Caution therefore arises as of future MSC transplantations within
inflamed CNS that characterize neurodegenerative and tumor
conditions [36]. Nevertheless, these adaptive cellular conditions
have significant pathological implications towards hypoxic solid
tumour development. In fact, brain tumour-derived cells which are
under hypoxic stress develop an adaptive response that includes an
increased rate of glycolysis and angiogenesis or undergo cell death
by promoting apoptosis and/or necrosis [37]. The metabolic
flexibility that enables MSC to survive under conditions character-
ized by hypoxia was recently shown to involve a microsomal
glucose-6-phosphate transporter [26], a protein not only regulating
intracellular glucose cycling but also involved in the regulation of
cell survival and chemotaxis through ATP-dependent calcium flux
[20,21,38].
While MSC are usually cultured under normoxic conditions
(21% oxygen), their in vivo (patho)physiological ‘‘niches’’ have a
much lower oxygen tension. Because of their plasticity, stem cells
are particularly sensitive to their environments, and oxygen
tension therefore becomes one developmentally important stimu-
lus in stem cell biology as it will play a role in the intricate balance
between cellular proliferation and commitment towards differen-
tiation [39,40]. Under hypoxic conditions, the major transcription
factor affecting gene regulation in stem cells is HIF-1 [41]. This
Figure 3. 3BP2 silencing abrogates MSC migration in response
to hypoxic culture conditions. MSC were transiently transfected
with scrambled sequences or with 3BP2 siRNA as described in the
Methods section. (A) Immunoblotting of 3BP2 protein expression was
evaluated in cell lysates from Mock (white bars) and siRNA (black bars)
experiments. Total RNA was extracted, and qRT-PCR was used to assess
3BP2 gene expression knockdown efficiency. Apoptotic cell death was
assessed by the fluorometric caspase-3 activity as described in the
Methods section. (B) Cells were harvested and seeded onto Boyden
chambers using gelatin-coated filters to assess cell migration under
normoxic or hypoxic culture conditions. (C) Cell migration was
quantified as described in the Methods section and expressed as x-
fold induction over Mock-transfected cells. Values of cell migration are
means of three independent experiments (*p,0.05 versus normoxic
mock); Bars, 6SD.
doi:10.1371/journal.pone.0021511.g003
Figure 4. Stable expression of HIF-1a increases 3BP2 basal
expression and MSC migration. MSC stably expressing a DODD HIF-
1a mutant (MSC-HIF) were generated as described in the Methods
section. (A) Basal migration of MSC and MSC-HIF was performed as
described in the Methods section. Values of cell migration are means of
three independent experiments (*p,0.05 versus normoxic MSC). (B)
Cell lysates were isolated, western blotting and immunodetection was
performed with anti-3BP2 and anti-GAPDH antibodies as described in
the Methods section. (C) Total RNA was extracted, and qRT-PCR was
used to assess 3BP2 gene expression. (D) Cell migration was quantified
as described in the Methods section in Mock- (white bars) and si3BP2-
(black bars) transfected MSC or MSC-HIF-1a. Values of cell migration are
means of three independent experiments (*p,0.05 versus normoxic
mock MSC or MSC-HIF); Bars, 6SD.
doi:10.1371/journal.pone.0021511.g004
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involved in angiogenesis, such as bFGF, VEGF, and the VEGF
receptors Flk-1 and Flt-1, as well as components of the plasmi-
nogen system including the urokinase receptor, and the inhibition
of plasminogen activator 1 [41,42]. Other transcription factors
activated by hypoxia include early growth response-1 (Egr-1),
which regulates MT1-MMP transcription [43,44]. Interestingly,
MSC isolated from Egr-1
2/2 mice abrogated MT1-MMP
functions in cell survival [25]. In the present study, we show that
gene silencing of HIF-1a suppressed MT1-MMP as well as 3BP2
gene induction by hypoxia. Prior silencing of MT1-MMP gene
expression also abrogated 3BP2 gene expression by hypoxia. This
is suggestive of a cascade of molecular events triggered by HIF,
and leading to MT1-MMP-mediated upregulation and possible
recruitment of 3BP2 to the plasma membrane that may, in part,
explain increased MSC migration. Interestingly, Egr-1 was
recently shown to regulate HIF-1a gene expression during hypoxia
[45]. While MT1-MMP was shown to trigger the expression of
VEGF, which is also a target gene product of HIF-1 and may
possibly contribute to an autocrine regulation of increased cell
migration [46,47], we propose that MT1-MMP-mediated regula-
tion of 3BP2 expression may be a key modulator in the proteolytic
and cell migratory oncogenic and immunomodulatory responses
of MSC under hypoxic conditions.
Figure 5. Gene silencing of MT1-MMP antagonizes the effects of hypoxia on 3BP2 gene expression. MSC were transiently transfected
with scrambled sequences (Mock, white bars) or MT1-MMP siRNA (black bars) as described in the Methods section. Cells were then cultured under
normoxic or hypoxic culture conditions. (A) Immunoblotting of MT1-MMP protein expression was evaluated in cell lysates from siRNA experiments.
Total RNA was extracted, and qRT-PCR was used to assess 3BP2, HIF-1a and MT1-MMP. Apoptotic cell death was assessed using the fluorometric
caspase-3 activity assay as described in the Methods section. (B) 3BP2 and HIF-1a gene expression were assessed by qRT-PCR in Mock-transfected
(open circles) and in siMT1-MMP-transfected (closed circles) cells that were subsequently cultured under hypoxic conditions. (C) MSC were transiently
transfected with either scrambled sequences or MT1-MMP siRNA as described in the Methods section. Cells were then cultured under normoxic or
hypoxic culture conditions, cell lysates were isolated, western blotting and immunodetection were performed with anti-3BP2 and anti-GAPDH
antibodies. Values in (A) and (B) are means of two independent experiments, each performed in triplicates (*p,0.05 versus mock control in (A) or
mock at time=0 hr hypoxia in (B)); Bars, 6SD.
doi:10.1371/journal.pone.0021511.g005
Figure 6. 3BP2 induction requires MT1-MMP cytoplasmic domain-mediated signalling. (A) MSC were transiently transfected with
pcDNA3.1 (Mock, white bars), a plasmid encoding full length MT1-MMP (Wt, black bars), or a plasmid encoding for a cytoplasmic domain-deleted
form of MT1-MMP (D-cyto, grey bars). Cells were then cultured under normoxic culture conditions, total RNA was extracted, and qRT-PCR was used to
assess 3BP2 gene expression. (B) Gelatin zymography of the conditioned media was used to demonstrate efficient cell surface targeting of the
respective Wt and D-cyto MT1-MMP recombinant proteins and subsequent ability to retain extracellular catalytic functions and to activate the
secreted latent proMMP-2 into active MMP-2. (C) Cell lysates were isolated, western blotting and immunodetection was performed with antibodies
recognizing the MT1-MMP catalytic or cytoplasmic domain, anti-3BP2 and anti-GAPDH as described in the Methods section. Values are means of two
independent experiments, each performed in triplicates (*p,0.05 versus Wt-MT1-MMP control); Bars, 6SD.
doi:10.1371/journal.pone.0021511.g006
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immune receptor-mediated signal transduction [48,49], and that
takes part in various cellular functions such as apoptosis [48] cell
differentiation [50], several signalling pathways [51], reorganiza-
tion of actin cytoskeleton, cell motility and cell adhesion [50]. Most
of the above-mentioned functions are also commonly shared by
MT1-MMP in angiogenic processes [52]. Interestingly, 3BP2
silencing is also associated with impaired activation of multiple
signalling events downstream of RANK, including actin reorga-
nization, Src, ERK, and JNK phosphorylation, and up-regulation
of osteoclastogenic factors [50]. Given the absence of predicted
HIF-1a binding sequence within the 3BP2 gene promoter, one
may consequently hypothesize alternate signal transduction
triggers to be involved in MSC adaptation upon low oxygen
environment. In fact, our data confirm that hypoxia-mediated
induction of 3BP2 requires a concerted MT1-MMP and HIF-1a
signalling. Among the possible chronological events taking place in
this HIF-1a/MT1-MMP/3BP2 signalling axis, one can envision a
recruitment and binding of 3BP2 at the membrane. Preliminary
data arising from immunoprecipitation experiments performed in
cells transfected with Wt-or D-cyto-MT1-MMP cDNA suggest
direct binding of 3BP2 to the cytoplasmic domain of MT1-MMP
(not shown). While recruitment of adaptor proteins such as
p130Cas and the kinase activity of Src [18,19] to MT1-MMP
suggest that such scaffolds already take place in MT1-MMP-
mediated cellular signalling, further studies will be required to
better understand the (patho)physiological impact of such
dynamic.
Finally, studies have indicated the ability of stem cell
populations, including MSC, to inhibit or downregulate immune
responses in vitro and in vivo [53]. MSC have recently been reported
to inhibit naive and memory antigen-specific T cells [54]. The
immunosuppressive qualities of MSC, which may facilitate evasion
of the immune system by a tumour, may in part involve major
histocompatibility complex (MHC) class I. Interestingly, pheno-
typic characterization of MSC by flow cytometry showed
expression of MHC class I alloantigens, but failed to elicit T cell
proliferative responses due to active suppressive mechanisms [55].
Recently, shedding of the tumour cell surface MHC class I chain-
related molecule A by MT1-MMP, a membrane bound matrix
metalloproteinase, was demonstrated to regulate sensitivity of
tumour cells to NK cell killing, a process which may add to tumour
immune evasion and contribute to tumour progression [56]. Such
cell surface proteolytic activity of MT1-MMP was also shown in
MSC to contribute to cleavage of CD44, another cell adhesion
molecule expressed at the cell surface of MSC, and to promote cell
migration [31,57].
MSC present a promising tool for cell therapy as proven
effective in pre-clinical studies. In fact, they are currently being
tested in US FDA-approved clinical trials for myocardial
infarction, stroke, meniscus injury, limb ischemia, graft-versus-
host disease and autoimmune disorders [58]. Clinical trials for
MSC injection into the CNS to treat traumatic brain injury and
stroke are also currently ongoing. Whether hypoxia/ischemia
alteration of MSC may influence endogeneous or exogenously
transplanted MSC biodistribution fate remains however to be
better investigated. Intravenous infusion of MSC was found to
reduce brain damage after transient global cerebral ischemia in vivo
[59]. These neuroprotective features of MSC are likely to occur
through some paracrine regulation mechanisms [60]. In support to
the MSC paracrine recruitment, MSC transplantation provided
trophic support to an ischemia/reperfusion injured liver model by
stimulating regeneration [61]. Therapeutic efficacy through MSC
mobilization was also demonstrated in a hindlimb ischemia model
[62].
Hypoxia is a tissue-specific condition that can promote
oncogenic processes. Indeed, in the bone marrow, the hypoxic
environment is important for maintaining the stemness, cell cycle,
survival and metabolism of MSC and HSC [63]. Moreover, the
low oxygen tension is thought to protect the genomic integrity of
stem cell populations by limiting the production of reactive oxygen
species by the mitochondrial respiration [64]. However, countless
evidences provide a role for hypoxia in the mobilization and
migration of MSC to the peripheral blood [28] and to tumors
Figure 7. Putative mechanisms involved in 3BP2 response to hypoxia and recruitment by MT1-MMP. Scheme summarizing the
mechanisms involved in 3BP2 response to hypoxia and potential recruitment by MT1-MMP. Hypoxia induces HIF-1a, which then upregulates MT1-
MMP gene transcription, MT1-MMP synthesis and targeting to the plasma membrane. The intracellular domain of MT1-MMP is mandatory to signal
potential 3BP2 recruitment and to trigger both cell migration and extracellular matrix (ECM) degradation. proMMP-2, latent form of matrix
metalloproteinase-2; MMP-2, active form of matrix metalloproteinase-2; TIMP-2; tissue inhibitor of MMP-2.
doi:10.1371/journal.pone.0021511.g007
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progression because of the heterotypic interactions within the
tumor stroma. Indeed, hypoxic cancer cells secrete various
cytokines, such as IL-6, VEGF, PDGF and FGF, that attract
and promote MSC proliferation and differentiation into tumor-
supporting cells [67,68]. The complex nature of the hypoxic tumor
microenvironment makes it pro-oncogenic for MSC, as opposed to
the hypoxic niche of the bone marrow, which preserves their
integrity and function.
In conclusion, our study provides unexpected original molecular
evidence linking the adaptor protein 3BP2 to oncogenic
transformation contribution of MSC in response to hypoxia. A
schematic representation is shown to summarize the possible
signalling mechanism that is triggered upon MSC hypoxic cues
and that could possibly lead to 3BP2 recruitment to MT1-MMP
and to MSC migration (Fig. 7). Furthermore, we document a new
molecular signalling axis driven by the intracellular domain of
MT1-MMP in concert with signalling requiring HIF-1a, and
which adds to the new roles of MT1-MMP as recently described in
energy-dependent regulation through non-proteolytic mechanisms
[69]. The sum of this evidence supports, in part, the oncogenic and
immunomodulatory adaptive mechanisms that could eventually be
targeted in MSC that contribute to hypoxic tumour development.
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